-
April 23, 2019 | Synspire Pharmaceuticals SNSP 113 Demonstrates Improvement in Abnormal Cystic Fibrosis Mucus and Pulmonary Disease
-
April 10, 2019 | Synspire Pharmaceuticals Receives Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis in the European Union
-
October 11, 2018 | Synspire Pharmaceuticals Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis
-
August 09, 2018 | Synspire Pharmaceuticals PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells
-
January 17, 2018 | Synspire Pharmaceuticals Novel Glycopolymer Proves Effective Against Antibiotic Resistance
-
November 02, 2017 | Synspire Pharmaceuticals Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference
-
October 18, 2017 | Synspire Pharmaceuticals Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis
Toggle navigation